Diabetes is a disease characterized by either the inability to produce enough insulin or a lack of cellular response to insulin. The resulting high blood sugar levels lead to myriad health issues including cardiovascular disease, vision loss, nerve damage, and kidney disease. Current therapies for glycemic control include metformin, sulfonylureas and PPAR-γ agonists. Newer modalities targeting the incretin axis include dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. A novel method for controlling glucose via the kidneys is inhibition of sodium glucose co-transporter 2 (SGLT2).